SELLAS Life Sciences Group, Inc. — Director's Dealing 2019

Mar 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2019-03-14

Reporting Person: Sarlis Nicholas J. (Chief Medical Officer and SVP)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-14	Stock Option (Right to Buy)	$1.38	A	50000	Acquired	2019-12-31	Common Stock (50000)	Direct

Footnotes

F1: All of the option shares will vest and become exercisable upon the closing of a Change of Control transaction (as defined in Mr. Sarlis' stock option grant notice), provided that the Reporting Person remains in continuous service with the Issuer on the vesting date.